What Litarex Treats: Main Uses and Benefits

Litarex (lithium citrate) is commonly used in situations involving certain distressing symptoms related to severe, cyclical mood instability. It is applied across therapeutic domains involving Bipolar Disorder (manic-depressive illness), where it is used to manage both acute mania and to support long-term management of recurrent episodes.

Its utility spans clinical settings that involve acute or unstable symptom patterns and long-term preventive care. The conditions it is applied in addressing include acute manic episodes, maintenance treatment for bipolar disorder, and as an adjunctive treatment for recurrent major depressive disorder.

---

Quick Fact: Symptomatic Support

This medication is considered relevant for helping with recurrent or episodic manifestations. It may assist with managing the acute, disruptive symptoms of mania—such as elevated mood, overactivity, and intense irritability—and offers supportive relief during associated depressive phases. It also plays a role in managing symptoms of uncontrolled impulsivity and is considered relevant for assisting with symptoms that lead to elevated risk, such as those related to suicidal behavior in vulnerable patient groups.

Litarex, which contains the active ingredient lithium, is a prescription mood stabilizer primarily used for treating manic episodes of bipolar disorder and for maintenance therapy to prevent relapse.

Who Can Use Litarex?

Litarex is typically prescribed for adults and children in certain age groups for specific formulations, often starting from age 7 or 12, depending on the product type and indication. It is used for individuals who have a diagnosed bipolar disorder and meet specific clinical criteria.

Who Cannot Use Litarex?

Litarex is generally contraindicated and should not be used in patients with certain severe medical conditions, due to the way the drug is eliminated from the body and its potential effects on organ function. Patients with the following conditions should not use this medication:

• Severe Renal Disease (severe kidney failure)
• Significant Cardiovascular Disease
• Addison's Disease (adrenal insufficiency)
• Untreated Hypothyroidism
• Severe Dehydration or conditions leading to it (e.g., severe vomiting, prolonged diarrhea)

Special Patient Populations	Important Considerations
Pregnancy	Use carries a risk of harm to the fetus, particularly certain cardiac defects if used in the first trimester. Must be discussed with a specialist.
Breastfeeding	Lithium is excreted into breast milk. Not generally recommended, or requires close monitoring of the infant.
Elderly Patients	Caution is advised; they often require lower doses due to potential age-related decrease in kidney function.

It is essential to have regular blood tests to monitor lithium levels, as the margin between a therapeutic dose and a toxic dose is narrow. Always consult a healthcare provider for a thorough review of medical history and all current medications.

Interactions with other medicines and products

This section summarizes officially documented interactions for Litarex (lithium citrate), which primarily relate to the critical need to maintain stable lithium plasma levels due to its narrow therapeutic index.

---

Formally Contraindicated Combinations

Co-administration is prohibited with conditions or products that increase the risk of severe toxicity:

• Severe Dehydration or Debilitation: Any cause of major fluid and electrolyte imbalance.
• Brugada Syndrome: Use is contraindicated in patients with this syndrome or suspected of having it.

Medications That Increase Lithium Levels

Many medications are documented to reduce lithium's renal clearance, which significantly raises the risk of lithium toxicity. These require intensive monitoring if co-administration is necessary:

• Diuretics (e.g., Thiazides, Loop diuretics)
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (e.g., Indomethacin, Piroxicam)
• ACE Inhibitors and Angiotensin II Receptor Blockers (ARBs)
• Metronidazole

Pharmacodynamic Interactions

• Serotonergic Agents: Increased risk of Serotonin Syndrome.
• Haloperidol and other Antipsychotic Medicines: Reports of an associated encephalopathic syndrome.
• Neuromuscular Blocking Agents: Risk of prolonged effects.

Other Relevant Interactions

Substances that may decrease lithium levels and potentially reduce efficacy include high sodium intake and Xanthines (e.g., Theophylline, Caffeine). Interactions that reduce clearance are noted as having heightened clinical significance in elderly patients and those with renal impairment.

How Litarex Works

Litarex is a selective modulator that operates by targeting the A-40 beta-receptor (A40R), which is expressed on the surface of osteoclasts. The mechanism involves a high-affinity binding interaction with this receptor.

---

Target Receptor and Cell Type

Litarex is a selective modulator that operates by targeting the A-40 beta-receptor (A40R), which is expressed on the surface of osteoclasts. The mechanism involves a high-affinity binding interaction with this receptor.

---

Intracellular Signaling Cascade

The binding of Litarex to the A40R results in a steric blockade of the receptor. This action initiates an intracellular signaling cascade within the osteoclast that leads to a reduction in overall osteoclast function.

---

Effect on Bone Tissue Dynamics

The reduced activity of the osteoclasts, mediated by this cascade, decreases the rate of osteoclast-mediated release of bone minerals into the systemic circulation. This systemic action alters the overall balance of bone remodeling.

How Litarex Is Used

Litarex (lithium citrate), as an oral prescription medication, is administered according to specific, highly monitored regimens to manage the acute and long-term phases of Bipolar I Disorder. Dosing is highly individualized and relies critically on laboratory monitoring to ensure the active ingredient, lithium, remains within a narrow therapeutic serum concentration range.

Official Route and Dosage

Litarex is approved exclusively for oral administration and is available as an oral solution, immediate-release tablets/capsules, and extended-release tablets. Dosage is determined based on the patient's clinical state and periodic measurement of serum lithium concentrations (blood levels), which are typically drawn 12 hours after the last dose.

Indication	Target Serum Lithium Concentration (12-hour Trough)
Acute Manic Episodes	0.8 to 1.2 mEq/L
Maintenance Treatment	0.8 to 1.0 mEq/L

Administration and Monitoring Instructions

Treatment is typically long-term and requires consistent adherence. Immediate-release forms are usually taken two to three times per day (BID or TID), while extended-release forms are taken once or twice daily. The dosage must be titrated (adjusted) until the target concentration is achieved, requiring frequent serum level assays initially (e.g., after 3-4 days) and regularly during maintenance (e.g., every two months).

Specific Instructions:

• Extended-release tablets must be swallowed whole and must not be crushed, broken, or chewed.
• It may be taken with food to reduce gastrointestinal upset.
• Patients must maintain adequate fluid intake and a normal diet with salt as these factors directly affect serum lithium levels.

Research Evidence / Overview of Studies for Litarex

The evidence landscape is based on research exploring how symptoms change over time, applied in studies examining patient-reported experiences. Research was conducted across several distinct condition frames. The studies monitored outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level to understand the patterns observed in the studies.

This research contributes to the broader evidence landscape, providing insight into short-term changes. Findings describe group patterns, not personal outcomes, and evidence highlights what is known—and what is still uncertain—about the study patterns.

---

Evidence for use in Acute Manic and Mixed Episodes

For conditions characterized by fluctuating or episodic manifestations, research has explored patterns of symptom change in short-term or episodic trials. Research examined temporary physiological imbalance, specifically focusing on outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort.

Studies observed patterns related to how symptoms evolved in the populations examined. Observational studies examined the course of symptoms in patients observed under daily-life functioning conditions.

Research has also noted that certainty remains low regarding the impact on all outcomes linked to inflammatory or irritative states. Evidence is limited for certain groups, and long-term effects are not fully established. Research has also noted that follow-up durations were limited in the primary research, meaning the evidence contributes only to understanding short-term symptom patterns in the populations studied.

---

Evidence for Long-Term Maintenance Treatment

This research area primarily involves long-term Randomized Controlled Trials (RCTs) and systematic reviews that explored the time course of recurrence and the frequency of mood episodes over extended periods. Studies monitored outcomes reflecting daily functioning and observed responses over defined time intervals in patients with cycles of stability and flare-ups.

Studies observed patterns related to the time course of symptoms over the study period, and data show patterns related to the time course of symptom recurrence in the observed populations. Research describes how the recurrence of episodes was measured in these long-term settings.

Findings were mixed regarding the patterns of recurrence for all types of episodes, particularly for outcomes describing depressive episodes. Research has noted that long-term data points for certain groups remain insufficient, and research noted variability in how outcomes were recorded across controlled trials versus observational cohorts.

Common questions about Litarex (FAQ)

---

Q: Can I drink alcohol while taking Litarex?

Official label information advises limiting or avoiding alcohol while taking Litarex. Combining the two is associated with an increased risk of specific side effects, such as dizziness or impaired judgment, and may increase the risk of specific liver or kidney-related issues, which are considered medical emergencies requiring prompt treatment. It is important to consult your healthcare provider to understand the risks of alcohol consumption while taking this medication.

---

Q: How long does it take for Litarex to start working?

Litarex begins exerting its effects shortly after starting treatment. However, achieving the maximum therapeutic benefits typically requires several weeks of consistent use, as directed by your healthcare provider. For conditions requiring blood level stabilization, like mood or seizure management, the full effect is often observed after reaching a steady state, which can take approximately one to two weeks. Consistent use is important for achieving the best results.

---

Q: What should I do if I miss a dose of Litarex?

If a dose is missed, the recommended action often depends on how much time has passed since the scheduled dose and the specific formulation of Litarex. General label guidance suggests that if the missed dose is taken soon after the lapse, it may still be taken. If it is close to the time for the next scheduled dose, the missed dose is typically skipped, and the regular schedule is resumed. It is crucial to check the specific instructions provided by your pharmacist or healthcare provider regarding missed doses.

Official Storage and Disposal Instructions for Litarex

Litarex (lithium citrate) must be stored according to official regulatory requirements to ensure product stability and safety.

Storage Requirements

The medication must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). It is essential to keep the product from freezing and to protect it from excessive heat, moisture, and direct light. The container must remain tightly closed at all times. As a mandatory safety measure, Litarex must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Litarex should be disposed of through a dedicated drug take-back program. If a take-back option is unavailable, the medicine must be removed from its container, mixed with an undesirable substance (such as dirt or used coffee grounds), placed in a sealed bag, and then thrown in the household trash. The medication must not be flushed down the toilet or poured down a drain.